Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.86 |
| ▸ | CES1 | P23141 | 8/20 | 0.82 |
| ▸ | CES2 | O00748 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463411 | 0.92 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9192692 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8515257 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL810234 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL28471077 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL10966855 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL4653611 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2819894 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL31152148 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2304645 | 0.90 | FAAH (1.00) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007121851-A1 | LIGHTENING AND/OR COLOURING AGENTS COMPRISING HALOGENATED KETONES | HENKEL AG & CO. KGAA (DE) | 2007-11-01 | — | — | WO | claimed |
| EP-1420771-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | Solvay Pharmaceuticals GmbH (DE) | 2004-05-26 | — | — | EP | claimed |
| WO-2003007923-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-01-30 | — | — | WO | claimed |
| CN-118562175-B | Block all-carbon-connected proton exchange membrane and preparation method and application thereof | 佛山大学 | 2025-04-01 | — | — | CN | disclosed |
| WO-2025057814-A1 | PHOTOCHROMIC COMPOSITION, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-03-20 | — | — | WO | disclosed |
| CN-118562175-A | Block all-carbon-connected proton exchange membrane and preparation method and application thereof | 佛山科学技术学院 | 2024-08-30 | — | — | CN | disclosed |
| EP-4245369-A2 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4246641-A1 | ELECTROLYTE, AS WELL AS ELECTROCHEMICAL APPARATUS AND ELECTRONIC APPARATUS CONTAINING THE SAME | Ningde Amperex Technology Ltd. (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-3865135-A2 | NEUROACTIVE STEROIDS FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3677259-A1 | USE OF ARACHIDONYL TRIFLUOROMETHYL KETONE | Mosaiques Diagnostics And Therapeutics AG (DE) | 2020-07-08 | — | — | EP | disclosed |
| WO-2007104582-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| EP-0300497-B1 | Optically active compound, process for producing same and liquid crystal composition containing same | CANON KK (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-5126071-A | Optically active compound, process for producing same and liquid crystal composition containing same | CANON KABUSHIKI KAISHA (JP) | 1992-06-30 | — | — | US | disclosed |
| US-4917817-A | Optical active compound, process for producing same and liquid crystal composition containing same | CANON KABUSHIKI KAISHA (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0300497-A1 | Optically active compound, process for producing same and liquid crystal composition containing same | CANON KABUSHIKI KAISHA (JP) | 1989-01-25 | — | — | EP | disclosed |
| EP-0002892-B1 | AMIDE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL OR VETERINARY COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-06 | — | — | EP | disclosed |
| US-4191775-A | ANTIANDROGENIC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-03-04 | — | — | US | disclosed |
| EP-0002892-A1 | Amide derivatives, process for their manufacture and pharmaceutical or veterinary compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | FAAH 1197/4885CES1 1071/4885CES2 2510/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | FAAH 854/4885CES1 915/4885CES2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.